NCT/Study#

NCT04398680 /

GSK-209627

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)

A Phase I Study to Evaluate the Pharmacokinetics and Safety of
Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple
Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function
(DREAMM 13)

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: